Abstract
A combination of L-dopa and carbidopa was given orally to 17 patients with metastatic melanoma. Maximum tolerated oral doses were given, up to 4 grams daily. No response was seen in 15 patients evaluable for response. Toxicity was considerable, with seven of 17 patients (41%) stopping treatment because of unacceptable gastrointestinal toxicity or postural hypotension. Contrary to previous anecdotal reports, there was no evidence that L-dopa/carbidopa treatment resulted in accelerated progression of metastatic melanoma. Orally administered L-dopa/carbidopa is ineffective as therapy for advanced melanoma when maximum tolerated doses are used.
Original language | English |
---|---|
Pages (from-to) | 85-87 |
Number of pages | 3 |
Journal | Journal of Investigative Dermatology |
Volume | 96 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 1991 |
Externally published | Yes |